This study founded that the expression of RUNX2 was positively related to the immune infiltration of CD4+ T cells, CD8+ T cells, B cells, neutrophils, DC cells, and macrophages in the breast cancer microenvironment. Here, RUNX2 is linked to breast carcinoma.